Minerva Neurosciences, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2021. Minerva is a clinical-stage biopharmaceutical company developing roluperidone for schizophrenia and MIN-301 for Parkinson’s disease. It has no approved products and has generated no product-sales revenue.
Financial results and liquidity
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $41.2 million |
| Research and development | $4.5 million | $4.6 million | $13.3 million | $18.5 million |
| General and administrative | $3.0 million | $3.5 million | $10.7 million | $13.5 million |
| Net income (loss) | $(9.2) million | $(8.1) million | $(28.6) million | $9.3 million |
| Net income (loss) per share, diluted | $(0.22) | $(0.19) | $(0.67) | $0.23 |
- Cash and liquidity: Cash, cash equivalents, and restricted cash totaled $65.7 million at September 30, 2021, up from $25.5 million at December 31, 2020. Management said this should fund commitments for at least 12 months after issuance of the financial statements.
- Cash flow: Nine-month operating cash use was $19.8 million, compared with $26.7 million in 2020. Financing provided $60.0 million from the sale of future seltorexant royalties; investing cash flow was zero.
- Debt-like obligation: The royalty sale is accounted for as debt financing. The related liability was $64.6 million at September 30, including $4.6 million of accrued non-cash interest. The filing estimates an effective annual interest rate of approximately 10.7%.
- Balance sheet: Total assets were $97.6 million, total liabilities $69.5 million, and stockholders’ equity $28.1 million. The company reported no traditional term-loan balance in the presented liabilities.
- Margins: Not meaningful because the company had no revenue in 2021 and has no commercial products.
Material changes and business developments
- The $41.2 million of 2020 nine-month revenue came from recognizing previously deferred Janssen collaboration amounts after Minerva opted out of the seltorexant development agreement. It was not recurring revenue and explains the comparison between 2020 profit and 2021 loss.
- Operating expenses declined year over year: nine-month R&D decreased by about $5.2 million, primarily following completion of the core Phase 3 roluperidone study and lower stock-based compensation; G&A decreased by about $2.8 million, largely due to lower stock compensation and severance costs.
- In January 2021, Royalty Pharma paid $60 million for Minerva’s seltorexant royalty interest. Minerva may receive up to an additional $95 million, contingent on clinical, regulatory, and commercial milestones. The upfront payment increased cash but is recorded as a liability; future interest expense is non-cash.
- Common shares outstanding were 42,721,566 at September 30, unchanged from year-end 2020.
Outlook, clinical updates, and risks
- Roluperidone: The 40-week open-label extension reported symptom and functional-score improvements, but lacked a placebo control, limiting interpretation. The preceding 12-week Phase 3 study did not meet its primary or key secondary endpoints in the intent-to-treat population.
- A pivotal bioequivalence study reported comparable pharmacokinetics between the planned commercial formulation and formulations used in earlier trials, with administration possible with or without food.
- On November 3, 2021, Minerva disclosed that the FDA denied its request for a pre-NDA meeting and indicated a Type C guidance meeting would be more appropriate. The company planned to request that meeting and had not changed its projected first-half 2022 NDA submission timing, subject to FDA feedback.
- Management expects continuing losses and negative operating cash flows and says additional capital will be needed to fund operations and later-stage development. Financing may dilute shareholders or be unavailable on acceptable terms; absent funding, programs could be scaled back or discontinued. MIN-301 spending and timing remained under evaluation.
- COVID-19 had not materially affected operations to date, but could disrupt trials, timelines, service providers, or access to capital. A securities class action concerning alleged statements about roluperidone was voluntarily dismissed, and the court closed the case on July 9, 2021.
- No specific financial earnings or revenue guidance was provided. The filing states there can be no assurance of regulatory approval or successful commercialization.
Important facts for investors to verify
- Whether FDA feedback at a future Type C meeting supports the planned roluperidone NDA submission, particularly given the Phase 3 trial’s failure to meet its primary endpoint.
- Whether the company’s $65.7 million of cash is sufficient for its development plans and when additional financing may be required.
- How estimates of future seltorexant royalties affect the $64.6 million royalty obligation and ongoing non-cash interest expense; whether any contingent Royalty Pharma milestone payments are achieved.
- Whether clinical development timelines or operations are materially affected by COVID-19 or other trial, regulatory, or financing risks.